Trial Profile
Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure (DAPTOREA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Daptomycin (Primary)
- Indications Gram-positive infections
- Focus Pharmacokinetics
- Acronyms DAPTOREA
- 10 Oct 2016 Status changed from recruiting to completed.
- 10 Jul 2014 New trial record